VALENTINA MOORE: Open Payments
NPI 1639650120 · O FALLON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$792 in 31 payments from 14 companies in 2025. Trend: 2023 $2,303 · 2024 $2,565 · 2025 $792
Food & beverage: $792
| Company | Payments | Amount |
|---|---|---|
| Insulet Corporation | 1 | $169 |
| ABBVIE INC. | 11 | $162 |
| GENZYME CORPORATION | 1 | $123 |
| Regeneron Healthcare Solutions, Inc. | 2 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $58 |
| Madrigal Pharmaceuticals | 2 | $43 |
| Janssen Biotech, Inc. | 2 | $35 |
| PFIZER INC. | 2 | $34 |
| Aimmune Therapeutics, Inc. | 2 | $32 |
| IRONWOOD PHARMACEUTICALS, INC | 1 | $19 |
Products named: DUPIXENT, OMNIPOD, RINVOQ, REZDIFFRA, ENTYVIO, TREMFYA, XELJANZ, ZENPEP.
Industry payments across MO — which companies pay providers there.
